Coloplast ASCLPBF 72 FCF Margin % is 14.36% as of Mar. 2026, which is 17% below its 10-year median of 17.34. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.91 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Coloplast AS ranks better than 91.29% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Coloplast AS's Free Cash Flow for the
three
months ended in Mar. 2026 was $157 Mil. Coloplast AS's Revenue for the
three
months ended in Mar. 2026 was $1,096 Mil. Therefore, Coloplast AS's FCF Margin % for the quarter that ended in Mar. 2026 was 14.36%.
The historical rank and industry rank for Coloplast AS's FCF Margin % or its related term are showing as below:
CLPBF'
s FCF Margin % Range Over the Past 10 Years
Min: 5.25 Med: 17.34 Max: 22.45
Current: 21.16
During the past 13 years, the highest FCF Margin % of Coloplast AS was 22.45%. The lowest was 5.25%. And the median was 17.34%.
CLPBF's FCF Margin % is ranked better than 91.29% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs CLPBF: 21.16
Coloplast AS FCF Margin % Related Terms
Coloplast AS FCF Margin % Historical Data
* Premium members only.
The historical data trend for Coloplast AS's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Coloplast AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Coloplast AS's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a FCF Margin % of 14.36% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coloplast AS and its competitors. This is 17% below median its historical median of 17.34. Over the past decade, Coloplast AS's FCF Margin % has ranged from 5.25 to 22.45. According to the industry distribution chart, Coloplast AS ranks #71 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Coloplast AS's FCF Margin % too high?
Coloplast AS's current FCF Margin % of 14.36% is 17% below median its 10-year median of 17.34. Over the past 10 years, this metric has ranged from a low of 5.25 to a high of 22.45. Based on the distribution chart, Coloplast AS ranks #71 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #71 out of 815 companies for FCF Margin %. This places Coloplast AS in the top 9% of its industry — outperforming the majority of peers. Historically, Coloplast AS's own FCF Margin % has ranged from 5.25 to 22.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coloplast AS and its competitors. Coloplast AS's current FCF Margin % is 14.36%, which is 17% below median its own 10-year median of 17.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.91, compared to a current price of $57.41 — trading 54.8% below its estimated fair value. The current FCF Margin % is 14.36%, which is 17% below median its 10-year median of 17.34. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current FCF Margin % is 14.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $57.41 is trading 54.8% below its estimated GF Value™ of $126.91.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
FCF Margin %: 14.36% (17% below median its 10-year median of 17.34)
GF Value™: $126.91 vs. price of $57.41 (54.8% below fair value)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
